Value Sense
CLOV
Clover Health Investments, Corp. (CLOV)
Last Price$3.4(0.9%)
Market Cap$1,625.6M
LTM P/E
(37.8x)
EPS growth
12.1%
PEGY
(3.1x)
Peter Lynch Fair Value
($1.1)
Overvalued (Peter Lynch formula)
(132.1%)
Stock quality
5/10
Good
CLOV
is 46.9% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

CLOV Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 13, 2025
LTM P/E
(37.8x)
EPS growth
12.1%
Dividend Yield
0.0%
PEGY
(3.1x)
Last share price
$3.4
Peter Lynch Fair Value
($1.1)
132.1% overvalued

Peter Lynch Fair Value Calculation

PEGY
(3.1x)
=
LTM P/E
(37.8x)
/
(
EPS growth
12.13%
+
Dividend yield
0.00%
)
Peter Lynch
Fair Value
($1.1)
=
Last share price
$3.4
/
PEGY
(3.1x)

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

CLOV EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

CLOV vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

Clover Health Investments, Corp. logo
Clover Health Investments, Corp.CLOV
(132.1%)
8.8%
(82.2%)
(3.1%)
Median Peer Set
10.7%
(25.4%)
1.2%
Cigna Corporation logo
Cigna CorporationCI
1,504.2%
26.6%
(93.1%)
0.1%
UnitedHealth Group Incorporated logo
UnitedHealth Group IncorporatedUNH
56.6%
8.9%
(35.7%)
3.6%
Elevance Health Inc. logo
Elevance Health Inc.ELV
53.3%
3.2%
0.5%
3.4%
Molina Healthcare, Inc. logo
Molina Healthcare, Inc.MOH
8.8%
19.3%
9.2%
2.9%
Humana Inc. logo
Humana Inc.HUM
(24.1%)
10.7%
(50.2%)
1.0%
CVS Health Corporation logo
CVS Health CorporationCVS
131.6%
4.2%
(43.6%)
1.2%
Centene Corporation logo
Centene CorporationCNC
39.9%
5.9%
27.4%
2.0%
Alignment Healthcare, Inc. logo
Alignment Healthcare, Inc.ALHC
91.0%
48.3%
(15.2%)
(4.7%)
Oscar Health, Inc. logo
Oscar Health, Inc.OSCR
44.1%
56.5%
N/A
0.3%

Explore more intrinsic value tools hub for CLOV

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is Clover Health Investments, Corp. fair value by Peter Lynch formula?

As of Mar 11, 2025, Clover Health Investments, Corp.'s fair value using the Peter Lynch formula is ($1.1) per share. The current price of $3.4 suggests Clover Health Investments, Corp. may be overvalued by this metric.

What is Clover Health Investments, Corp. Price to Earnings (P/E) ratio?

As of Mar 11, 2025, Clover Health Investments, Corp.'s P/E ratio is (37.8x). This is calculated by dividing the current share price of $3.4 by the Earnings per Share (EPS) for the trailing twelve months, which is ($0.1). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Clover Health Investments, Corp. earnings per share (EPS)?

Clover Health Investments, Corp. earnings per share (EPS) for the twelve months ending Mar 11, 2025, was ($0.1), a 12.1% growth year-over-year.